In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Semorex Inc.

Latest From Semorex Inc.

Start-Up Previews (4/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, The New Wave in Gastroenterology, features profiles of Algenix Inc., IntraPace Inc., MediGus Ltd. and Semorex Inc. Plus these Selected Start-Ups across Health Care: Isogenica Ltd., Opt-e-scrip Inc., Renovis Inc. and LLC.

Semorex Inc.

Semorex hopes to create plastic antibodies that fit into targets to serve many purposes; as therapeutics, as drug screening and design tools, as separation reagents, and as diagnostics. In drug discovery, for example, Semorex aims to supply researchers with large quantities of artificial receptors for use in high throughput arrays. This will be particularly useful in cases where natural receptors are difficult to isolate or are not available in large quantities.

The New Wave in Gastroenterology

Gastroenterology, once a market comprised of large, reusable pieces of equipment like endoscopes, ushers in a new era of minimally invasive surgical disposables. Indeed, minimally invasive procedures make it possible for surgical devices to encroach upon drug franchises in several multi-billion dollar markets, including gastroesophageal reflux disease and obesity.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Semorex Inc.
  • Senior Management
  • Morris Priwler, CEO
  • Contact Info
  • Semorex Inc.
    Phone: (972) 8 972 5539
    43 Emek Refaim St.
    Jerusalem, 93141